Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHILLES: Secukinumab for Achilles Tendon Enthesitis in Psoriatic Arthritis and Axial Spondyloarthritis
2016-000972-91Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and enthesitis comparing Secukinumab with Placebo (2 arms). Primary endpoint: Resolution of Achilles tendon enthesitis. Started Apr 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)axial spondyloarthritis (axSpA)enthesitis
Beyond the preview
Go deeper on 2016-000972-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000972-91.